NRG-GY008 CLOSURE NOTICE 

NRG-GY008: A PHASE II EVALUATION OF COPANLISIB (BAY 80-6946) (IND #130822), A SELECTIVE INHIBITOR OF PI3KCA, IN PATIENTS WITH PERSISTENT OR RECURRENT ENDOMETRIAL CARCINOMA HARBORING PIK3CA HOTSPOT MUTATIONS 

It has been determined that NRG-GY008 will not open to the second stage of accrual and is closed to patient entry effective August 7, 2017.

Documents can be found on NRG Oncology.

 

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.
Twitter

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address